Ebert Bjarke, Wafford Keith A, Deacon Stephen
Department of Electrophysiology, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark.
Pharmacol Ther. 2006 Dec;112(3):612-29. doi: 10.1016/j.pharmthera.2005.04.014. Epub 2006 Jul 28.
Chronic insomnia affects a significant proportion of young adult and elderly populations. Treatment strategies should alleviate nighttime symptoms, the feeling of nonrestorative sleep, and impaired daytime function. Current pharmacological approaches focus primarily on GABA, the major inhibitory neurotransmitter in the central nervous system. Benzodiazepine receptor agonists (BzRA) have been a mainstay of pharmacotherapy; the classical benzodiazepines and non-benzodiazepines share a similar mode of action and allosterically enhance inhibitory chloride currents through the GABA(A) receptor, a ligand-gated protein comprising 5 subunits pseudosymmetrically arranged around a core anion channel. Variations in GABA(A) receptor subunit composition confer unique pharmacological, biophysical, and electrophysiological properties on each receptor subtype. Classical benzodiazepines bind non-selectively to GABA(A) receptors containing a gamma2 subunit, whereas non-benzodiazepine hypnotics bind with higher relative affinity to alpha1-containing receptors. The non-benzodiazepine compounds generally represent an improvement over benzodiazepines as a result of improved binding selectivity and pharmacokinetic profiles. However, the enduring potential for amnestic effects, next day residual sedation, and abuse and physical dependence, particularly at higher doses, underscores the need for new treatment strategies. Novel pharmacotherapies in development act on systems believed to be specifically involved in the regulation of the sleep-wake cycle. The recently approved melatonin receptor agonist, ramelteon, targets circadian mechanisms. Gaboxadol, an investigational treatment and a selective extrasynaptic GABA(A) receptor agonist (SEGA), targets GABA(A) receptors containing a delta subunit, which are located outside the synaptic junctions of thalamic and cortical neurons thought to play an important regulatory role in the onset, maintenance, and depth of the sleep process.
慢性失眠影响着相当一部分年轻成年人和老年人群体。治疗策略应缓解夜间症状、睡眠无恢复感以及日间功能受损的情况。当前的药物治疗方法主要聚焦于γ-氨基丁酸(GABA),它是中枢神经系统中的主要抑制性神经递质。苯二氮䓬受体激动剂(BzRA)一直是药物治疗的主要手段;经典苯二氮䓬类药物和非苯二氮䓬类药物具有相似的作用模式,并且通过GABA(A)受体变构增强抑制性氯离子电流,GABA(A)受体是一种配体门控蛋白,由围绕核心阴离子通道假对称排列的5个亚基组成。GABA(A)受体亚基组成的变化赋予了每种受体亚型独特的药理学、生物物理学和电生理学特性。经典苯二氮䓬类药物非选择性地与含有γ2亚基的GABA(A)受体结合,而非苯二氮䓬类催眠药与含有α1亚基的受体具有更高的相对亲和力。由于结合选择性和药代动力学特征的改善,非苯二氮䓬类化合物总体上比苯二氮䓬类药物有所改进。然而,遗忘效应、次日残留镇静作用以及滥用和身体依赖的持久可能性,尤其是在高剂量时,凸显了对新治疗策略的需求。正在研发的新型药物疗法作用于被认为特别参与睡眠-觉醒周期调节的系统。最近获批的褪黑素受体激动剂雷美替胺作用于昼夜节律机制。加波沙朵是一种正在研究的治疗药物,是一种选择性突触外GABA(A)受体激动剂(SEGA),作用于含有δ亚基的GABA(A)受体,这些受体位于丘脑和皮质神经元的突触连接之外,被认为在睡眠过程的起始、维持和深度方面发挥重要调节作用。